Transforming Cardiovascular Care with HealthTab™
Avricore Health Inc. (TSXV: AVCR) is setting a remarkable precedent in healthcare technology with its innovative product, HealthTab™. This platform is making waves by being deployed in a significant new pilot program, spearheaded by Barts Health NHS Trust, in partnership with UCL Partners and the British Heart Foundation (BHF). The initiative focuses on delivering inclisiran cholesterol-lowering injections through community pharmacies, marking an essential transition in patient care.
Key Benefits of HealthTab™ Integration
HealthTab™ serves a pivotal role in bridging secondary-prevention care within the NHS framework. This is a substantial leap forward that goes beyond simple screenings to incorporate therapy-linked workflows. The synergy between HealthTab™ and the Ortus-iHealth system is vital, directly linking pharmacy operations to hospital clinical systems. This integration amplifies the capabilities of HealthTab™ as a crucial infrastructural element for pharmacy-based care within the NHS.
Validation of HealthTab™ Technology
The inclisiran pilot not only showcases HealthTab™ as a trusted technology partner but also solidifies its significance in a leading cardiovascular program. This initiative immensely broadens HealthTab's potential market by allowing it to engage in comprehensive lipid management, thus amplifying Avricore's footprint in UK community pharmacy networks while adhering to NHS policy that emphasizes the decentralization of chronic-condition management.
Funding and Support for the Initiative
This pilot, backed by a generous grant of £198,000 from BHF, illustrates the ongoing momentum toward decentralizing cardiovascular therapy delivery. By shifting appropriate services to community pharmacies, it aims to alleviate hospital congestion, providing better care for individuals with long-term conditions in their local areas. Building upon the ELoPE-CVD program, the pilot aspires to enhance access to preventive heart care and efficient lipid management, particularly for patients at heightened cardiovascular risk.
HealthTab™ Expanding Role in Secondary Prevention
The integration of HealthTab™ into secondary prevention signifies a profound evolution for both the platform and community pharmacies. Through this pilot, local pharmacies are now equipped to safely administer and monitor advanced lipid-lowering therapies for patients already diagnosed with cardiovascular disease. This marks a crucial expansion in how HealthTab™ is utilized, placing it at the center of a modern pharmacy-supported treatment network.
Community Pharmacy Initiatives
The pilot aims to explore various capabilities within community pharmacies, including:
- Administering inclisiran injections once solely the domain of hospital lipid clinics.
- Accelerating therapy initiation for patients who are on long waiting lists for specialist care.
- Identifying at-risk patients through specialized cholesterol testing enabled by HealthTab™.
- Providing structured follow-ups and monitoring as a fundamental aspect of an integrated lipid management pathway.
The NHS's ambitious objective to prevent up to 150,000 cases of heart attacks, strokes, and dementia over the next decade emphasizes the importance of improving the detection and management of high-risk conditions like high cholesterol. This journey involves elevating the role of community pharmacies, intricately linking them to shared digital records that support collaborative healthcare.
Significance of HealthTab™ in Clinical Pathways
HealthTab™ is gaining prominence within major cardiovascular programs as a reliable platform for community diagnostics and workflow enhancement, sustaining primary and secondary prevention efforts concurrently. Its integration with the Ortus platform substantially elevates its value by transitioning HealthTab™ from merely a diagnostic tool to an essential component of full care-team support. This evolution is vital in aligning with the NHS's 10-year strategy that encourages shared, interoperable health records.
Commitment to Quality and Innovation
HealthTab™ is designed as a robust, comprehensive solution for community-based point-of-care testing (POCT) networks. It incorporates leading-edge instruments, cloud software, standardized workflows, and extensive training and support for pharmacies. Central to its operation is a secure, cloud-based platform that ensures a seamless connection between point-of-care analyzers and patient results, promoting effective public health reporting and performance evaluation.
Partnering with CEQAL Inc., a pioneer in quality management for clinical laboratories, HealthTab™ upholds rigorous standards of analytical performance and reliability. This partnership ensures consistent accuracy and traceability across all testing sites, fostering widespread confidence in the test results.
About Avricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a trailblazer in pharmacy services dedicated to developing early-stage technologies that enhance pharmacy practices and patient care. With its flagship product, HealthTab™, Avricore's mission is to make health information accessible, promoting a vast network of rapid testing devices within community pharmacies.
Frequently Asked Questions
What is HealthTab™?
HealthTab™ is an innovative platform designed to facilitate quick and efficient health diagnostics in community pharmacies, including the administration of advanced therapies.
How does HealthTab™ benefit community pharmacies?
HealthTab™ enhances pharmacies' roles by enabling them to provide crucial health services such as cholesterol testing and administering medications, thereby improving patient care.
What is the NHS pilot about?
The NHS pilot, in collaboration with Avricore Health, focuses on administering inclisiran injections through community pharmacies to expand accessibility to cardiovascular care.
What role does Ortus-iHealth play?
Ortus-iHealth integrates HealthTab™ with hospital clinical systems, ensuring seamless data sharing and improving care coordination for patients.
How is Avricore Health contributing to public health?
By enhancing access to testing and treatment through community pharmacies, Avricore Health aims to improve health outcomes in preventative heart care and long-term condition management.
